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Abstract: Metformin therapy lowers blood glucose in type 2 diabetes by targeting various pathways
including hepatic gluconeogenesis. Despite widespread clinical use of metformin the molecular
mechanisms by which it inhibits gluconeogenesis either acutely through allosteric and covalent
mechanisms or chronically through changes in gene expression remain debated. Proposed mechanisms
include: inhibition of Complex 1; activation of AMPK; and mechanisms independent of both Complex
1 inhibition and AMPK. The activation of AMPK by metformin could be consequent to Complex
1 inhibition and raised AMP through the canonical adenine nucleotide pathway or alternatively
by activation of the lysosomal AMPK pool by other mechanisms involving the aldolase substrate
fructose 1,6-bisphosphate or perturbations in the lysosomal membrane. Here we review current
interpretations of the effects of metformin on hepatic intermediates of the gluconeogenic and glycolytic
pathway and the candidate mechanistic links to regulation of gluconeogenesis. In conditions of
either glucose excess or gluconeogenic substrate excess, metformin lowers hexose monophosphates
by mechanisms that are independent of AMPK-activation and most likely mediated by allosteric
activation of phosphofructokinase-1 and/or inhibition of fructose bisphosphatase-1. The metabolite
changes caused by metformin may also have a prominent role in counteracting G6pc gene regulation
in conditions of compromised intracellular homeostasis.
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1. Introduction: The Metformin Mechanism and AMPK Activation
Type 2 diabetes is a chronic disease of increasing prevalence in association with obesity and
positive energy balance. It manifests as a progressive rise in blood glucose and increased hepatic
glucose production by gluconeogenesis. Metformin (dimethyl biguanide) is the most commonly
prescribed therapy for this condition and one of its main therapeutic effects is the inhibition of hepatic
gluconeogenesis [1,2]. This may be elicited through either acute inhibition of gluconeogenic flux or
through chronic changes in gene expression. Despite several decades of research on the mechanisms
by which metformin and other biguanides that preceded it in diabetes therapy, elicit inhibition of
gluconeogenesis there remains much debate on which of the candidate mechanisms has a prominent
role in its therapeutic effects.
One of the most extensively studied mechanisms for metformin is the activation of the signalling
kinase AMPK [3,4]. The canonical mechanism involves accumulation of metformin in mitochondria by
virtue of its positive charge at physiological pH causing inhibition of the respiratory chain at the level of
Complex 1 [5–7] resulting in compromised adenine nucleotide phosphorylation potential and a rise in
AMP promoting activation of the energy sensor, AMPK. This in turn phosphorylates a range of target
proteins [8,9]. AMPK is a serine threonine kinase that was first identified as a negative regulator of
hepatic acetyl-CoA carboxylase and HMG-CoA reductase, key regulators of fatty acid and cholesterol
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biosynthesis [10]. Its role in the inhibition of de novo fatty acid synthesis is firmly established and
accordingly there is good consensus for AMPK activation accounting for the inhibition of fatty acid
synthesis by metformin [3,4]. But a key outstanding issue is whether activation of AMPK has a role in
the blood glucose lowering effect of metformin and if so to what extent relative to other mechanisms
that manifest at low therapeutic doses of metformin [4,11]. A second question is whether the activation
of AMPK by metformin is mediated by inhibition of Complex 1 or by other mechanisms that may
manifest at lower metformin concentrations, which have negligible effect on cell adenine nucleotide
levels [4]. Although AMPK is conventionally regarded as an energy sensor, recent studies identified
fructose 1,6-bisphosphate (F1,6P2) as a metabolite regulator of AMPK [12–14]. This intermediate
of glycolysis and gluconeogenesis links the PFK1/FBP1 cycle and aldolase and is present in liver
at substantially lower concentrations than proximal and distal intermediates. Because of its low
concentration there is little data on the effects of low metformin doses on this metabolite. The purpose
of this paper is to discuss current understanding of the metformin mechanism on gluconeogenesis
and of AMPK activation in relation to linked changes in cellular metabolites that may control enzyme
activity through either allosteric mechanisms or control of gene expression.
2. AMPK Activation
2.1. Control by Adenine Nucleotides, Calcium and F1,6P2
AMPK is a heterotrimer comprising a catalytic subunit (α) and two regulatory (β and γ) subunits.
These subunits are encoded by seven genes giving rise to α1, α2 (Prkaa1,2), β1,β2 (Prkab1,2), γ1,γ2γ3
(Prkag1,2,3) which enable 12 combinations of units and thereby potential diversity of response to cater
for tissue-specific functions. AMPK is activated allosterically by binding of AMP to the γ subunit and
by phosphorylation of Thr172 within an activation loop in the α-subunit [8]. The upstream kinases
include LKB1 (Liver kinase B1) and CaMKK2 (Ca2+-calmodulin dependent protein kinase 2) [15–18].
LKB1 is constitutively active but is recruited to AMPK by allosteric mechanisms linked to adenine
nucleotide binding to the γ subunit or by F1,6P2 dissociation from aldolase which promotes formation
of a complex linking LKB1 and AMPK at the lysosomal surface. CaMKK2 is activated by an increase in
calcium. Effects of metformin on agonist-induced Ca2+ oscillations and Ca2+ release from intracellular
stores have been reported but not in connection with AMPK activity [19]. A third kinase for Thr172
phosphorylation is TAK1 (transforming growth factor β activated kinase-1) which remains as yet
a contentious candidate after LKB1 and CAMKK2 [20]. However a role for TAK1 in activation of
lysosomal AMPK has been reported [21,22] and a liver-selective TAK1 deletion mouse model is
characterized by dysregulation of both lipid metabolism and autophagy consistent with compromised
AMPK regulation [23].
The β subunits comprise myristoylated N-termini (which target AMPK to lysosomes and
mitochondria), carbohydrate-binding domains (β-CBD), β-linkers and C-terminal domains (β-CTD)
which constitute part of the binding sites of allosteric activators (A-769667, 991). The γ subunits are
stabilized in the AMPK complex through an interdomainβ-sheet formed with theβ-CTD. They comprise
4 repeats of a motif termed the cystathionine β-synthase domain. One such domain binds AMP
constitutively and another two bind AMP, ADP or ATP with different affinity enabling allosteric
activation by the AMP/ATP ratio [8,9]. Binding of AMP and ADP promote phosphorylation of Thr172
by LKB1 and more modestly by CAMKK2 [24,25] and both AMP and ADP restrict dephosphorylation
of Thr172 by protein phosphatase 2C [25,26]. However only AMP promotes allosteric activation [26].
The fractional activation by AMP is greater for γ1 and γ2 than for γ3 at physiological ATP [25]. Isoform
diversity is also apparent from subcellular location, since α2 but not α1 complexes localize to the
nucleus [27].
Although AMPK in all subcellular pools (cytoplasmic, lysosomal, mitochondrial and nuclear) can
be regulated by adenine nucleotides through the canonical pathway, other “non-canonical” mechanisms
for the lysosomal pool are triggered by either changes in F1,6P2 which affects LKB1 mediated
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phosphorylation [12] or Galectin-9 recruitment which promotes TAK1 mediated phosphorylation [21,22].
A key function of lysosomal AMPK is the stimulation of autophagy which is the process of degradation
of long-lived proteins and macromolecular structures for recycling. The lysosomes are the ultimate
destination for this process and harbour complex signalling pathways for the reciprocal control of
AMPK and mTORC1, a major driver of protein homeostasis [28]. Activation of lysosomal AMPK by
low glucose is triggered by depletion of F1,6P2 the substrate of FBP1 and aldolase, which promotes
formation of a multiprotein complex at the lysosome comprising aldolase, the vacuolar H+-ATPase,
the pentameric Ragulator Complex and the scaffolding protein AXIN which binds both AMPK and
LKB1 [12,14]. Activation of cytoplasmic AMPK is contingent on moderately raised AMP (2–3 fold)
and formation of a complex comprising AXIN, LKB1 and AMPK [14]. Activation of mitochondrial
AMPK is dependent on greater elevation of AMP (~6-fold), which promotes phosphorylation of
AMPK by LKB1 independently of AXIN [14]. The functional consequence of this hierarchy of AMP
thresholds is that moderately compromised phosphorylation potential which activates lysosomal and
cytoplasmic but not mitochondrial AMPK promotes inhibition of lipogenesis and protein synthesis
by targeting ACC1, SREBP-1c and mTORC1 whereas more substantial ATP depletion is required to
enhance mitochondrial fatty acid oxidation (by phosphorylating ACC2) or mitochondrial fragmentation
through phosphorylation of MFF (mitochondrial fission factor) which is the receptor for dynamin like
protein-1 on the mitochondrial outer membrane [29–31].
2.2. Changes Linked to Nutritional State or the Gluconeogenic/Glycolytic Poise
Liver AMPK is activated by fasting and inactivated by refeeding with the α1 isoform showing a
greater and more rapid response than α2 [32]. Insulin and glucagon do not seem to be involved [33],
however changes in the ATP/ADP ratio and thereby AMP as well as F1,6P2 (see below) are all candidate
regulators. Low glucose is often implicated as the trigger for AMPK activation [9], however in liver the
mechanistic link may be the change in directionality of flux from glycolysis in the absorptive state to
gluconeogenesis during fasting. Ethanol is a strong negative regulator of liver AMPK causing both a
decrease in Thr172 phosphorylation and a decline in the α-unit protein level. Proposed mechanisms
include oxidative stress and ceramides [34,35]. Whether the more reduced cytoplasmic NAD/NADH
redox state is involved in the negative regulation by ethanol and refeeding through consequent
metabolite changes linked to the dehydrogenase equilibria remains to be tested. In hepatocytes
showing higher AMPK activity in a glucose-free medium with gluconeogenic precursors compared
with high glucose [33], candidate mechanisms may involve changes in compartmentation of enzymes
of glycolysis and gluconeogenesis. Possible candidates include: glucokinase which translocates from
the nucleus to the cytoplasm [36] and aldolase and FBP1 which colocalise at low glucose but not at
high glucose when FBP1 translocates to the nucleus [37]. The interaction between FBP1 and aldolase is
unique to the liver isoform (aldolase-B) and is regulated by AMP, F6P, F2,6P2, F1,6P2. A proposed
hypothesis is that there are distinct pools of aldolase-B linked to glycolysis or gluconeogenesis [37].
This implies different occupancy by F1,6P2 and thereby differential involvement of aldolase pools in
AMPK activation.
2.3. Activation by Biguanides and Mitochondrial Inhibitors (The Canonical Pathway)
Biguanides and rotenone (a Complex 1 inhibitor), cause activation of AMPK that parallels the
compromised phosphorylation potential [38–40], taking into account that changes at low metformin may
be at the limits of assay detection. Ota and colleagues [40] expressed the yeast internal NADH-quinone
oxidoreductase (NDI1) and provided supportive evidence that Complex 1 inhibition accounts for
the metformin activation of AMPK, a conclusion endorsed by other approaches [41]. NDI1 is one of
two yeast NADH-Q oxidoreductases and is both rotenone-insensitive and lacks a proton translocase.
NDI1 faces the mitochondrial matrix unlike the external isoform that faces the intermembrane space.
The latter serves to oxidize cytoplasmic NADH because yeast lacks shuttles for reducing equivalents.
NDI1 can substitute for functional defects in mammalian Complex 1 because it localizes in the correct
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orientation in mitochondria, when expressed in mammalian cells [42]. NDI1 is thereby, a very useful
tool to test for Complex 1 involvement as distinct from other candidate mitochondrial targets such as
ATP-synthase [7] in the metformin mechanism.
2.4. Metformin Activation of Lysosomal AMPK (Non-Canonical Pathways)
Zhang and colleagues [43] showed, using mouse knock-down models that activation of liver
AMPK by 50 mg/kg metformin is contingent on both AXIN and LAMTOR1 implicating activation of
the lysosomal pool. Likewise in intact mouse embryonic fibroblasts and in isolated vesicles from these
fibroblasts incubated with metformin, the activation of AMPK was linked to a complex comprising the
vacuolar H+-ATPase, Ragulator, AXIN and LKB1 and with reciprocal dissociation of mTOR/Raptor
also implicating a predominant lysosomal pool. Recently Jia and colleagues [21,22] identified a role for
cytoplasmic lectins termed galectins, which are recruited to the lysosome during stress resulting in
mTOR inhibition (galectin-8) and AMPK activation by TAK1 (galectin-9) [21]. In the macrophage THP-1
cell line metformin induced the recruitment of galectin-9 and galectin-8, to a vesicular location [22].
Whether this effect is linked to metformin accumulation in lysosomes [44], inhibition of cathepsins [45]
or a more pleiotropic effect of metformin on lysosomes remains to be determined.
2.5. AMPK Activation by A-769662, 991 and AMP Analogues Does Not Mimic Metformin on Gluconeogenesis
Small molecule activators of AMPK (A-769662 and 991) that bind to an allosteric site at the
interface between the α-unit and the carbohydrate binding domain on the β-unit [46,47] or that are
precursors of AMP analogues (C13 for C2 [48]) are potential tools to test the role of AMPK activation
because they promote both allosteric activation of AMPK and phosphorylation of its downstream
targets, and do not interact with FBP1 unlike AICAR that was used in prior studies. In hepatocytes
they promote comparable phosphorylation of the AMPK substrate acetyl-CoA carboxylase (Ser79)
as metformin but have converse effects on the partitioning of DHA between gluconeogenesis and
glycolysis, on glycolysis from glucose, and on G6P levels during gluconeogenic flux [49,50]. Although
non-specific effects of the compounds cannot be firmly excluded, the opposite effects from metformin
on both gluconeogenic flux and cell G6P despite substantial AMPK activation, argues against a role for
AMPK activation in the acute inhibition of gluconeogenic flux [49,50]. This does not exclude a role for
AMPK on gluconeogenesis through effects on gene expression (Section 4).
3. Adaptive Changes in Hepatic Intermediates of Glycolysis and Gluconeogenesis
3.1. Effects of Nutritional State, Glucagon, Fatty Acids and Exercise on F1,6-P2
Control of intracellular metabolite homeostasis has been less extensively studied and is less well
understood than blood glucose homeostasis [51]. The liver presents unique challenges for intracellular
homeostasis because it receives the products of carbohydrate and protein digestion directly from the
gut via the portal vein and is thus exposed to higher and more variable concentrations of sugars
(glucose and fructose) and amino acids than peripheral tissues. A key role of the liver is the clearance
of these substrates for energy interconversion and storage. Efficient control of substrate clearance is
uniquely served by liver-specific enzyme isoforms.
Allosteric control of glycolysis in the liver is by feed-forward activation by substrate supply.
This contrasts with feed-back inhibition in other tissues which is controlled by metabolic demand.
Feed-forward activation of hepatic glycolysis by high glucose after a meal involves: (1) glucose-induced
activation of glucokinase by dissociation from its inhibitory protein GKRP in the nucleus and
translocation to the cytoplasm; (2) elevation in hepatic G6P and F6P; (3) F6P-induced activation of
the bi-functional enzyme PFKFB1, which generates and degrades the regulatory metabolite, F2,6P2;
(4) allosteric activation of PFK1 by the raised F2,6P2; (5) elevation in F1,6P2 the PFK1 product which in
turn activates pyruvate kinase. Figure 1A,B shows the relative concentrations of the intermediates of
glycolysis-gluconeogenesis in rat liver in the fed and fasted state [52]. The first 3 intermediates G6P,
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F6P and F1,6P2 are approximately 2-fold higher in the fed state consistent with feed-forward activation
of glucose disposal. The concentrations of the substrate and products of aldolase (F1,6P2, DHAP,Ga3P)
are substantially lower than more distal metabolites.
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also implicate regulation at PFK1/FBP1. Although F2,6P2 determines PFK1 regulation by glucose and 
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Figure 1. Liver concentrations of intermediates of glycolysis and gluconeogenesis. (A) Metabolic
intermediates of glycolysis and gluconeogenesis. (B) Concentrations of key metabolites in rat liver in
the fed and fasted state; data from Bergmeyer, HU [52]). (C,D) Liver metabolites in fed and fasted rats
treated with glucose (2 g/kg, 10 min) or glucagon (1 mg/kg, 2 min); data from [53,54]. (E) Effects of
1 mM oleate on metabolites in hepatocytes from fasted rats, data from [55]. (F) Rat liver metabolites in
rested and exercised rats, data from [56]. * p < 0.05 fasted vs. fed
In liver F1,6P2 is the product of PFK1 during glycolysis and of aldolase during gluconeogenesis.
This intermediate shows adaptive changes that mostly parallel the activity of PFK1 (Figure 1C,D).
For example, glucagon phosphorylates the bifunctional enzyme PFKFB1 that generates and degrades
F2,6P2, causing a rapid decline in F2,6P2 (activator of PFK1 and inhibitor of FBP1) with a slower
decline in F1,6P2 [54] and concomitant elevation in G6P and F6P (Figure 1C,D). Likewise the decline
in F1,6P2 in response to fatty acids (Figure 1E, [55]) can be explained by high-affinity inhibition of
PFK1 by acyl-CoA [56]. The converse changes in F1,6P2 and F6P/G6P during exercise (Figure 1F, [57])
also implicate regulation at PFK1/FBP1. Although F2,6P2 determines PFK1 regulation by glucose
and glucagon [58] other allosteric effectors of PFK1 (including AMP, Pi and citrate) determine the
stimulation of glycolysis by anoxia [59] and metformin [49,60] which occurs despite a decline in F2,6P2.
3.2. AICAR Has a Unique Effect on F1,6P2
AICAR (5-amino-4-imidazole carboxamide riboside), which is phosphorylated to ZMP,
an intermediate in purine biosynthesis, is a strong inhibitor of gluconeogenesis and has a unique
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effect on intermediary metabolites characterized by a large increase in F1,6P2 and DHAP (Figure 2A),
when the cytoplasmic ZMP is in the high mM range, because ZMP inhibits FBP1 with a Ki of 370 µM
by binding to the AMP inhibitor site [61]. The fold increase in F1,6P2 is far greater with DHA
(dihydroxyacetone) compared with lactate and pyruvate (40-fold vs. 2-fold) as substrate, consistent
with the higher gluconeogenic flux from DHA [62]. It is noteworthy that whilst AICAR almost totally
inhibits FBP1 as shown by the 40-fold increase in F1,6P2 with DHA in hepatocytes, it is not a selective
inhibitor of FBP1 and also inhibits glycolysis in hepatocytes and other cell types in part by inhibition of
PFK1 [63,64]. In addition because of sequestration of phosphate in ZMP, AICAR also lowers ATP by
depleting inorganic phosphate and thereby oxidative phosphorylation [65]. It is therefore unsuitable
as a tool for either AMPK activation or for FBP1 inhibition.
3.3. Similarities in Cross-Over Plots for Biguanides and Respiratory Chain Inhibitors
The inhibition by guanidine derivatives of mitochondrial respiration with substrates of Complex
1 has been recognized for ~60 years [66,67]. Although the therapeutic relevance was questionable,
detailed flux control analysis by Halestrap and colleagues showed that the respiratory chain has
a very high flux control coefficient on gluconeogenic flux from lactate and pyruvate [68], meaning
that inhibition of glucose production can occur at a very small fractional decrease in oxidative
phosphorylation that may not manifest as a significant decline in cell ATP. Owen & Halestrap [69]
determined the effects of different inhibitors of the mitochondrial respiratory chain on intermediates of
glycolysis/gluconeogenesis in rat hepatocytes and showed raised PEP, 3PG, 2PG and lowered triose
phosphates (DHAP,Ga3P), F1,6P2, F6P, G6P (Figure 2B, red data curve). This is a distinct crossover
plot from that of AICAR, but is identical to that of phenformin [70] in rat liver perfused with three
gluconeogenic precursors (lactate/pyruvate, DHA, xylitol). Owen & Halestrap proposed that the
decrease in ATP/ADP inhibits the phosphoglycerate kinase/Gapdh equilibria [69]. Their later work
with metformin on rat liver in vivo [6] showed broadly similar results except for triose phosphates
and F1,6P2 which were not decreased (Figure 2B, blue data curve). Lowering of triose phosphates
and F1,6P2 by respiratory chain inhibitors [69] and phenformin [70] was associated with a substantial
(>50%) decline in the ATP/ADP ratio, whereas the lack of lowering of triose phosphates and F1,6P2,
by metformin in vivo was not associated with a decline in the total (free+bound) ATP/ADP ratio [6].
This suggests that the “target site” for inhibition of gluconeogenesis is at PFK1/FBP1 for modestly
compromised phosphorylation potential, with unchanged or raised F1,6P2 [6], but at PGK/Gapdh
with a decline in F1,6P2 for more severe inhibition of the respiratory chain and phosphorylation
potential [69,70]. Accordingly, there is no evidence for unequivocal lowering of F1,6P2 by a modest
metformin dose [6].
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 18 
 
the cytoplasmic ZMP is in the high mM range, because ZMP inhibits FBP1 with a Ki of 370μM by 
binding to the AMP inhibitor site [61]. The fold increase in F1,6P2 is far greater with DHA 
(dihydroxyacetone) compared with lactate and pyruvate (40-fold vs. 2-fold) as substrate, consistent 
with the higher gluconeogenic flux from DHA [62]. It is noteworthy that whilst AICAR almost totally 
inhibits FBP1 as shown by the 40-fold increase in F1,6P2 with DHA in hepatocytes, it is not a selective 
inhibitor of FBP1 and also inhibits glycolysis in hepatocytes and other cell types in part by inhibition 
of PFK1 [63,64]. In addition because of sequestration of phosphate in ZMP, AICAR also lowers ATP 
by depleting inorganic phosphate and thereby oxidative phosphorylation [65]. It is therefore 
unsuitable as a tool for either AMPK activation or for FBP1 inhibition. 
3.3. Similarities in Cross-Over Plots for Biguanides and Respiratory Chain Inhibitors 
The inhibition by guanidine derivatives of mitochondrial respiration with substrates of Complex 
1 has been recognized for ~60 years [66,67]. Although the therapeutic relevance was questionable, 
detailed flux control analysis by Halestrap and colleagues showed that the respiratory chain has a 
very high flux control coefficient on gluconeogenic flux from lactate and pyruvate [68], meaning that 
inhibition of glucose production can occur at a very small fractional decrease in oxidative 
phosphorylation that may not manifest as a significant decline in cell ATP. Owen & Halestrap [69] 
determined the effects of different inhibitors of the mitochondrial respiratory chain on intermediates 
of glycolysis/gluconeogenesis in rat hepatocytes and showed raised PEP, 3PG, 2PG and lowered 
triose phosphates (DHAP,Ga3P), F1,6P2, F6P, G6P (Figure 2B, red data curve). This is a distinct 
crossover plot from that of AICAR, but is identical to that of phenformin [70] in rat liver perfused 
with three gluconeogenic precursors (lactate/pyruvate, DHA, xylitol). Owen & Halestrap proposed 
that the decrease in ATP/ADP inhibits the phosphoglycerate kinase/Gapdh equilibria [69]. Their later 
work with metformin on rat liver in vivo [6] showed broadly similar results except for triose 
phosphates and F1,6P2 which were not decreased (Figure 2B, blue data curve). Lowering of triose 
phosphates and F1,6P2 by respiratory chain inhibitors [69] and phenformin [70] was associated with 
a substantial (>50%) decline in the ATP/ADP ratio, whereas the lack of lowering of triose phosphates 
and F1,6P2, by metformin in vivo was not associated with a decline in the total (free+bound) 
ATP/ADP ratio [6]. This suggests that the “target site” for inhibition of gluconeogenesis is at 
PFK1/FBP1 for modestly compromised phosphorylation potential, with unchanged or raised F1,6P2 
[6], but at PGK/Gapdh with a decline in F1,6P2 for more severe inhibition of the respiratory chain and 
phosphorylation potential [69,70]. Accordingly, there is no evidence for unequivocal lowering of 
F1,6P2 by a modest metformin dose [6]. 
 
Figure 2. Crossover plots of metabolites of gluconeogenesis and glycolysis in liver or isolated 
hepatocytes. (A) Effects of AICAR (500 μM) in hepatocytes incubated with 10 mM lactate + 1 mM 
pyruvate [61]. (B) Effects of mitochondrial inhibitors (DCMU, dichlorophenyl dimethylurea) [69] or 
phenformin [70], in rat hepatocytes incubated with 10 mM lactate + 1 mM pyruvate (red) or effects of 
metformin on rat liver in vivo [6] (blue). 
Figure 2. Crossover plots of metabolites of gluconeogenesis and glycolysis in liver or isolated
hepatocytes. (A) Effects of AICAR (500 µM) in hepatocytes incubated with 10 mM lactate + 1 mM
pyruvate [61]. (B) Effects of mitochondrial inhibitors (DCMU, dichlorophenyl dimethylurea) [69] or
phenformin [70], in rat hepatocytes incubated with 10 mM lactate + 1 mM pyruvate (red) or effects of
metformin on rat liver in vivo [6] (blue).
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Other studies on the control of gluconeogenesis in the fetal/neonatal transition also showed
crossover points at either aldolase or PFK1/FBP1 [71]. Crossover plots at PFK1/FBP1 make teleological
sense insofar that PFK1 and FBP1 are highly regulated by allosteric effectors [58]. Support for FBP1 in
the metformin mechanism was provided by Hunter and colleagues [72] who generated a mouse model
for AMP-insensitive FBP1 and showed compromised efficacy of metformin (250 mg/kg) in this model.
This data does not exclude composite effects of metformin on both FBP1 and PFK1. Hepatocyte studies
targeting the PFK1/FBP1 locus by either depletion of F2,6P2 with a kinase-deficient variant of PFKFB1
or using aurintricarboxylic acid, a potent inhibitor of PFK1 (that mimics citrate inhibition) provide
support for a role for PFK1 in the metformin mechanism [49,50]. Allosteric effectors of PFK1 and FBP1
that are known to be regulated by metformin in a direction consistent with a crossover point between
F6P and F1,6P2 include: AMP (raised), Pi (raised), citrate (lowered), and G3P (lowered) [49,50]. There
is limited metabolite data for the direct AMPK activators (A-769662, 991) that bind to the allosteric site.
However, these compounds unlike metformin do not lower G6P and neither do they mimic the effects
of metformin on the redox state [49,50].
3.4. Metformin Has a Biphasic Effect on the Mitochondrial NADH/NAD Redox State
Two independent groups reported inhibition of Complex 1 (NADH:ubiquinone oxidoreductase)
by high millimolar metformin, in hepatocyte suspensions and mitochondria from metformin-treated
rats [5,6]. This was supported by an increase in the 3-hydroxybutyrate/acetoacetate ratio, which indicates
an increase in the mitochondrial NADH/NAD ratio through the 3-hydroxybutyrate dehydrogenase
equilibrium [73], and confirmed in later studies [74,75]. Bridges and colleagues [7] used purified
Complex 1 and assays for 3 sequential steps of the catalytic cycle (NADH oxidation, intramolecular
electron transfer and ubiquinone reduction) and showed that metformin is a reversible, non-competitive
inhibitor for the ubiquinone reduction reaction, with an IC50 in the millimolar range (~20 mM). Although
this is ~300 fold higher than the [metformin] in the hepatic portal vein and ~100-fold higher than
the concentration in the liver [76], metformin is estimated to accumulate in the matrix of energized
mitochondria to 100-fold higher concentrations [7]. Accordingly the calculated matrix metformin at
a portal vein concentration of 60 µM [76] is close to the IC50 [6,7]. Nonetheless, this issue remains
contentious because subcellular fractionation studies do not support such high intramitochondrial
concentrations [44,77]. However, cells pre-loaded with 14C-metformin, lose metformin very rapidly
when transferred to metformin-free medium [49,60], and likewise mitochondria lose metformin during
the isolation procedure [6]. Accordingly, the calculated mitochondrial content [6,7] is a more valid
estimate than measurements after subcellular fractionation, and is not far removed from measurements
of 14C-metformin in hepatocyte monolayers washed rapidly [49,60], if one assumes a fractional
mitochondrial volume of 10% [78] and a 100-fold gradient [7].
Recent studies by Madiraju and colleagues [79,80], showed that a 3–5 fold lower dose of
metformin (50 mg/kg) than was used by Owen & Halestrap [6] caused a more oxidized mitochondrial
NADH/NAD redox state as determined from both the liver and plasma 3-hydroxybutyrate/acetoacetate
ratio. This novel seminal finding was later corroborated by studies on the renal mitochondrial
redox state which is more oxidized after 50 mg/kg metformin [81] but more reduced after 125 mg/kg
metformin [82]. Our recent studies on mouse and rat hepatocytes showed that metformin has a
biphasic effect on the mitochondrial redox state such that 100 µM metformin which corresponds to a
cell load of 1–2 nmol/mg protein (therapeutic equivalent) causes a more oxidized whereas a 5-fold
higher concentration cause a more reduced redox state [50]. This confirms that the more oxidized
mitochondrial redox state in vivo after a low metformin dose [79,80] is a direct effect of metformin on
the liver.
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3.5. Candidate Mechanisms for the Oxidized Mitochondrial NADH/NAD State
Madiraju and colleagues proposed that the more oxidized mitochondrial NADH/NAD redox state
at low metformin is explained by direct inhibition of mitochondrial glycerophosphate dehydrogenase
(mGPD) [79,80], a component of the respiratory chain that spans the inner membrane and transfers
reducing equivalents from G3P on the cytoplasmic side to ubiquinone in the respiratory chain,
bypassing Complex 1 [83]. In liver, mGPD activity is low compared with other tissues [83]. Nonetheless
changes in mGPD activity (by protein overexpression or irreversible inhibition) in hepatocytes associate
with corresponding changes (more reduced or more oxidized, respectively) in the mitochondrial
NADH/NAD redox state [50]. However to date, the inhibition of mGPD by therapeutic levels of
metformin remains contentious because it has not been replicated in three other laboratories [50,84,85],
the most recent of these used four independent mGPD assays [85]. Since mGPD is regulated allosterically
by calcium [83], an indirect effect of metformin through allosteric or covalent mechanisms cannot be
unequivocally excluded. Nonetheless in the absence of replication of metformin inhibition of mGPD
activity, other mechanisms need to be considered.
An alternative mechanism is uncoupling of respiration. Cameron and colleagues [86] proposed
compromised coupling of the redox and proton pumping domains of Complex 1 by metformin to
explain a more oxidized NADH/NAD state in liver mitochondria. Batandier and colleagues compared
metformin and rotenone and noted mild uncoupling by metformin (but not by rotenone) as determined
from increased oxygen consumption with concomitant inhibition of ROS production linked to reverse
electron transport [87]. The latter has been replicated in other studies with low metformin [88,89] and
is attributed to an indirect pleiotropic effect of metformin resulting from a decrease in the driving force
for proton pumping against the proton gradient [89].
3.6. Metformin Effects on the Cytoplasmic NAD/NADH State and Glycerol 3-P (G3P)
Metformin (at low or high doses) causes a more reduced cytoplasmic NAD/NADH redox state
as determined from the lactate/pyruvate ratio [5,6,79,80,90]. The effect of high metformin (associated
with a reduced mitochondrial state) has been attributed to inhibition of Complex 1 [5,6] while the
effect of low metformin (associated with a more oxidized mitochondrial redox state) was attributed to
inhibition of mGPD [79,80] which transfers reducing equivalents from the cytoplasm to mitochondrial
ubiquinone pool (via the glycerophosphate shuttle) [83]. However in liver, the malate aspartate
shuttle has a more prominent role in transfer of reducing equivalents than the glycerophosphate
shuttle because of the low activity of mGPD [50,83,85,91]. The malate aspartate shuttle involves
an electrogenic transmitochondrial exchange of aspartate for glutamate and H+ [92] which is very
sensitive to mitochondrial membrane potential [93,94]. Accordingly, the more reduced cytoplasmic
NAD/NADH by low metformin is consistent with mitochondrial depolarisation [89,95] although an
increase in membrane potential has also been reported [77].
Liver cell G3P is either increased [79,80] or decreased by metformin [49,50,96]. Candidate effectors
of changes in G3P are: the NAD/NADHcyt redox state; the activity of mGPD and substrate supply
(Figure 3). Cytoplasmic glycerophosphate dehydrogenase (cGPD), catalyses the reversible NAD/NADH
coupled interconversion of G3P and DHAP, and accordingly a more reduced cytoplasmic NAD/NADH
ratio predicts an increase in the G3P/DHAP ratio. The mitochondrial enzyme mGPD catalyses the
irreversible conversion of G3P to DHAP coupled to transfer of electrons to the ubiquinone pool in
the respiratory chain and accordingly G3P is decreased by overexpression of mGPD and also by
mitochondrial uncoupling [49,50]. Substrate supply also increases G3P either moderately as occurs at
high glucose or more substantially with fructose (8-fold) and xylitol (80-fold) [97–99]. Changes in G3P
by metformin may therefore result from multiple possibly opposing mechanisms.
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3.7. The Metformin Mechanism on Gluconeogenic Flux: Deductions from Cell Metabolites
Proposed mechanisms for the acute inhibition of gluconeogenic flux by metformin include:
(i) activation of AMPK [3]; (ii) t decr ase in the ATP/ADP ratio acting on the glyceraldehyde
phosphate dehydrogenase and phosphoglycera e kinase equilibria [6,69]; (iii) an increase in the
cytoplasmic NADH/NAD ratio acting on the l ctate dehydrogenase equilibrium decreasing the
cytoplasmic and mitochondri l pyruvate [6,79,80]; (iv) allosteric control at FBP1 and PFK1 which are
regulated by multiple activators or inhibitors including AMP, Pi, citra e and G3P [49,50,58,72].
AMPK activa on c n be disc unted for the rapid mechanism(s) bec use selective activators of
AMPK do not mimic metformin on gluconeogenic flux [11,49,50]. The decr ase in the ATP/ADP
ratio would have a role in conditions of substant al ATP depletion as oc urs w th phenformin and
mit chondrial inhibitors with a crossover point between DHAP a d 3PG (Figure 2B) but not with a
metf rmi ose causing negligible ATP d plet on with a crossover point between F6P and F1,6P2 [6].
The increase in the cytoplasmic NADH/NAD predic s greater inhibit on of gluconeogenesis from
reduced substrates such as lactate and glycerol compared with pyruvate and dihydroxyacetone.
Ma iraju and colleagues proposed hat inhibition of mGPD accounts for inhibition of gluconeogenesis
through a more reduced cytoplasmic NAD/NADH [79,80] and showed that k ock-dow of mGPD
mimics the m tformin effect on th cytoplasmic redox state in Sprague Dawley rats. In additi n
metformin inhibited gluconeogenesis from r duced (la tate, glycerol) but not from oxidiz d (pyruvate,
DHA) substrates in hepatocytes from Spragu Dawley rats. Two comments are warran ed. Fi st,
most f not all other hepatocyte udies show higher basal rates of gluconeogenesis fr m DHA than
from eith r lacta e or glycerol, regardless of substrate concentration [62], contrary to the l wer rat
from DHA relative to lactate [79]. Second, inhibition by met ormin of gluconeogenesis from lactate
and glyc ol was greater than 50%. Given that ATP depletion by metformin is greater with lactate
and pyruv than with glucose [23], and it is also greater with reduc d than oxidiz d substrates [50],
it is possible that ATP deple io accounts f r the inhibition with reduc d substrates [79]. Calza and
colleagues [10 ] argued against the redox m chanism based on inhib tion of gluconeog nesis from
lactate with ethanol but not 30 µM metformin in the perfus rat liver [100].
T simultaneously test th redox hypothesis and the PFK1/FBP1 site in the metformin mechanism
we used ox dized (DHA) and reduced (xylitol and glycerol) substrates and compared metfor in with
an inhibitor of the malate aspartate shuttle, which promotes a more reduced cytoplasmic NADH/NAD
redox state compared wit metformin [50]. We found modest inhibition of gluconeogenesis with DHA
in the ab en e of ATP depletion but trends of ATP depl i n with metformin in c mbination with
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the reduced substrates (glycerol and xylitol). The latter conditions are associated with raised G3P,
which may explain the compromised ATP. This underscores the need for parallel analysis of cell ATP
in all measurements of gluconeogenesis in isolated hepatocytes. Inhibition of the malate aspartate
shuttle, which has a greater impact on the cytoplasmic NAD/NADH redox state, than low metformin,
attenuated total xylitol metabolism [50], whereas metformin had a greater impact on the partitioning
of substrate between gluconeogenesis and glycolysis. This supports a predominant role for metformin
control at the PFK1/FBP1 site relative to a redox mechanism. Whilst these studies do not exclude
an effect of metformin on gluconeogenesis from lactate, which is discussed in detail elsewhere [101],
they underscore the role of the PFK1/FBP1 site in the metformin mechanism.
Hunter and colleagues [72] tested the hypothesis that metformin inhibits gluconeogenesis by
an analogous mechanism to AICAR by inhibiting FBP1 at the AMP allosteric site. They showed
that a mouse model with an AMP-insensitive FBP1, is resistant to the acute blood glucose lowering
effect of AICAR and of a metformin dose (250 mg/kg) that causes a 2-fold increase in the AMP/ATP
ratio. This is consistent with a crossover point with metformin between F1,6P2 and F6P as was shown
previously [6]. Another mechanism linked to the raised AMP by metformin is inhibition of glucagon
signalling through inhibition of adenylate cyclase [102]. Accordingly, three candidate mechanisms link
raised AMP with inhibition of gluconeogenic flux through glucagon signalling, inhibition of FBP1 and
activation of PFK1.
4. Control of Gene Expression of Gluconeogenic Enzymes by Metformin and AMPK Activation
4.1. Interactions between AMPK Signalling and PKA Signalling in the Metformin Mechanism
A role for changes in gene expression in the metformin inhibition of gluconeogenesis is suggested
by studies in human type 2 diabetes showing lack of acute inhibition of hepatic glucose production
within 4 h of intravenous administration of metformin [103], implicating chronic changes in gene
expression to account for metformin efficacy during chronic therapy [2]. Gene expression profiling of
livers of obese db/db mice 2 h after administration of metformin (50 or 400 mg/kg) identified repression
of G6pc as one of 12 genes regulated by metformin [104]. G6pc encodes glucose 6-phosphatase, which
catalyses the final reaction in hepatic glucose production. This enzyme also has a crucial role in
regenerating inorganic phosphate in conditions of raised G6P [51]. Gene expression of G6pc like Pck1
(encoding phosphoenolpyruvate carboxykinase) is induced several-fold (>10-fold) by cell permeable
cAMP-analogues and this induction is attenuated by metformin [11,105,106]. The lower mRNA
levels for both G6pc and Pck1 in hepatocytes from a mouse model with a gain of function mutation
in the AMPK-γ1 subunit (D316A) with a ~2.5-fold increase in AMPK activity supports a role for
AMPK activation in the repression of both G6pc and Pck1 in basal non-stimulated conditions [107].
This attenuated G6pc and Pck1 expression manifests in hepatocytes isolated from the mice but not
in vivo [107]. Isolated hepatocytes from genetic or drug/diet-treated models are a powerful approach
to track the hepatocyte “status” independently of secondary hormonal and substrate changes that may
have an overriding effect in vivo. Candidate transcription factors for the AMPK-dependent repression
of Pck1 and G6pc include CRTC2 (CREB regulated transcription factor 2, also known as TORC2)
and CBP (CREB binding protein), where CREB is the cyclic AMP response element binding protein
activated by glucagon signalling and the down-stream transcription factor target PGC1-alpha, which
itself regulates the expression of G6pc and Pck1 [4,11]. Increased cAMP degradation by activation of
PDE4 is another candidate mechanism by which AMPK activation could counteract G6pc and Pck1
induction by cAMP signalling [108]. However, despite extensive evidence for counter-regulation by
AMPK activation of cAMP-mediated induction of G6pc and Pck1 [4], studies on hepatocytes from
AMPK-deficient mice showed virtually identical G6pc repression by metformin (≥0.5 mM) as control
hepatocytes [11].
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4.2. Metformin Counter-Regulation of Glucose Induction of G6pc
A distinguishing feature between transcriptional regulation of Pck1 and G6pc, is that whereas both
genes are activated by cAMP-signalling only G6pc is induced by high glucose by mechanism(s) that are
at least in part mediated by ChREBP, the Carbohydrate response element binding protein [60,109–111].
High glucose concentration causes activation of ChREBP by translocation from the cytoplasm to the
nucleus and recruitment to its target genes. The metabolite trigger is not glucose itself, because gene
induction is abolished by hexokinase inhibitors and enhanced by inhibition of G6P hydrolysis with
a chlorogenic derivative, which markedly raises G6P [110,111]. Although G6P is often regarded a
candidate trigger of ChREBP activation based on bioinformatic considerations [112], the metabolite
mechanism is more complex because depletion of F2,6P2 abolishes the glucose induction of ChREBP
target genes [111]. ChREBP is regulated by covalent modification as well as by metabolite control
and an inhibitory role for AMPK activation was proposed (reviewed in [113]). However, more recent
work suggests an inhibitory effect of raised AMP, which may contribute to some of the effects that
were previously attributed to AMPK activation [113]. In rat hepatocytes, metformin counteracts the
induction by high glucose of G6pc and other ChREBP target genes including Pklr and also Txnip and
it inhibits the recruitment of ChREBP to both the G6pc and Pklr gene promoters [60]. These effects
of metformin are associated with lowering of G6P which also occurs in hepatocytes from AMPKα1,
α2-KO mice [49,60]. Although the exact mechanism by which metformin represses G6pc through
AMPK-independent mechanisms [11] remains to be elucidated, a role for metabolite control of ChREBP
recruitment to the G6pc promoter [60] through either raised AMP [113] or lowered G6P and F2,6P2 [60]
is currently the most plausible hypothesis.
5. Perspectives
There is widespread consensus that the activation of AMPK by metformin first reported 20 years
ago occurs at therapeutic doses of the drug [3,4] and is involved in the inhibition of lipogenesis [3,10].
However what is less clear is the contribution of AMPK activation to the suppression of hepatic glucose
production. When asking the latter question, it is important to distinguish between the chronic effects
of metformin on gluconeogenesis that are mediated by repression of the G6pc and Pck1 genes resulting
in lower protein levels as distinct from the rapid effects of metformin on gluconeogenic flux that are
independent of changes in G6pc and Pck1 at the protein level.
For the rapid mechanism(s) on gluconeogenesis, the cumulative evidence is that activation of
AMPK does not inhibit gluconeogenic flux. Small molecule activators of AMPK that target either the
allosteric activator site or the AMP site and do not target FBP1 [48] have modest but opposite effects
to metformin on gluconeogenic flux [11,49]. The rapid but modest inhibition of gluconeogenic flux
by metformin is best explained by changes in allosteric effectors of FBP1 and PFK1 [49,72]. These
allosteric effectors include raised AMP which is an inhibitor of FBP1 and activator of PFK1 and raised
Pi and lowered citrate which activate and inhibit respectively, PFK1 [58]. Whether the more reduced
cytoplasmic NAD/NADH redox state caused by metformin has an additional role in restricting the
metabolism of lactate or glycerol remains as yet contentious [79,80,100,101].
AMPK activation counteracts cAMP-mediated induction of bothG6pc andPck1 [105,106]. However,
there is also evidence for repression of G6pc but not Pck1 by metformin through AMPK-independent
mechanism(s) [11]. The question whether the latter AMPK-independent repression of G6pc by
metformin is quantitatively important relative to other AMPK-mediated mechanisms is relevant to the
potential therapeutic value of selective AMPK activators for blood glucose control in type 2 diabetes.
Several points are noteworthy regarding the metformin repression of G6pc. First, the link between
metformin and G6pc repression has been identified by non-biased approaches in animal models of
obesity and hyperphagia predisposed to diabetes [104]. Second, G6pc catalyses the final reaction in
hepatic glucose production but also has a major role in maintaining intrahepatic metabolite homeostasis,
as supported by the marked induction in animal models of hyperphagia such as the ob/ob mouse or
elevated G6P [51,114]. Third, G6pc and Pck1 are oppositely regulated by high glucose [110,111], and also
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by gluconeogenic precursors such as dihydroxyacetone and glycerol, which like high glucose induce
G6pc but repress Pck1 [111,115]. Because G6pc and Pck1 are regulated co-ordinately by cAMP-linked
mechanisms and likewise by AMPK activation [105,106], but oppositely by nutrient excess, irrespective
of whether the substrate is glucose or gluconeogenic precursors [110,115], measurement of both genes
may help discriminate between AMPK-dependent and metabolite linked mechanisms which are
independent of AMPK [49]. Type 2 diabetes is commonly associated with nutrient excess which
predicts compromised intracellular homeostasis. Recent studies have reported lack of efficacy of
metformin in healthy non-diabetic people as well as in newly diagnosed well-controlled type 2
diabetes [116,117]. Although several factors may interact with the efficacy of metformin on endogenous
glucose production, further work on the metformin mechanism should focus on cell and animal models
with compromised intracellular metabolite homeostasis that more closely simulate the dysregulation
in poorly controlled type 2 diabetes, to determine whether AMPK-independent repression of G6pc by
metformin predominates in the compromised metabolic state.
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Abbreviations
ACC acetyl-CoA carboxylase
AICAR 5-amino-4-imidazole carboxamide riboside
AMPK AMP-activated protein kinase
cGPD cytoplasmic glycerophosphate dehydrogenase
ChREBP Carbohydrate response element binding protein
DHA dihydroxyacetone
DHAP dihydroxyaceyone phopsphate
FBP1 fructose 1,6-bisphosphatase-1
F6P fructose 6-phosphate
F1,6P2 fructose 1,6-bisphosphate
F2,6P2 fructose 2,6-bisphosphate
G6P glucose 6-phosphate
Ga3P glyceraldehyde 3-phosphate
G3P glycerol 3-phosphate
LKB1 liver kinase B1
mGPD mitochondrial glycerophosphate dehydrogenase
MFF mitochondrial fission factor
PEP phosphoenolpyruvate
PFK1 phosphofructokinase-1
2PG 2-phosphoglycerate
3PG 3-phosphoglycerate
TP triose phosphates
ZMP AICA-ribotide
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